Michael Charles Ryan - 12 Jul 2021 Form 4 Insider Report for Kiromic Biopharma, Inc. (KRBPQ)

Role
CHIEF BIOINFORMATICS RESEARCH OFFICER
Signature
/s/ Michael Ryan
Issuer symbol
KRBPQ
Transactions as of
12 Jul 2021
Net transactions value
$0
Form type
4
Filing time
02 Aug 2021, 15:05:23 UTC
Previous filing
27 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRBP Common Stock Other $0 +50,189 $0.000000 50,189 13 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRBP Restricted Stock Units Other $0 +31,991 $0.000000 31,991 12 Jul 2021 Common Stock 31,991 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securites were acquired pursuant to a Membership Interest Purchase Agreement dated as of June 14, 2021 among Kiromic Biopharma, Inc., InSilico Solutions, LLC and Michael Ryan.
F2 Each restricted stock unit is the economic equivalent of one share of Kiromic Biopharma, Inc. common stock.
F3 The vesting schedule is such that 25% of the RSUs vest on June 30, 2022, and the remainder will vest at a rate of 1/36th per month for 36 months thereafter.

Remarks:

CHIEF BIOINFORMATICS RESEARCH OFFICER